Biya Josette, Dury Sandra, Perotin Jeanne-Marie, Launois Claire, Dewolf Maxime, Deslée Gaëtan, Lebargy François
Department of Respiratory Diseases, Reims University Hospital.
EA 4683 Medical and Pharmacological Sciences.
Medicine (Baltimore). 2019 Nov;98(44):e17768. doi: 10.1097/MD.0000000000017768.
Relapsing polychondritis (RP) is a rare immune-mediated disease affecting cartilaginous structures. Respiratory tract manifestations are frequent and constitute a major cause of morbidity and mortality. The present review of the literature was designed to assess the efficacy of tumor necrosis factor alpha (TNF-α) inhibitors in respiratory tract involvement of RP.A MEDLINE literature search was performed from January 2000 to December 2016 to identify all studies and case reports of anti-TNF-α therapy in RP. Articles published in English or French concerning patients with respiratory tract involvement were eligible. Two authors (JB, FL) independently reviewed and extracted data concerning each patient and 2 personal cases were added. Treatment efficacy was assessed according to systemic and/or respiratory criteria.A total of 28 patients (mean age: 41.6 years; 16 females/12 males) were included in the final analysis. Anti-TNF-α therapy was associated with improved health status and respiratory symptoms in 67.8% and 60.1% of cases, respectively.These results suggest that TNF-α inhibitors could be considered for the treatment of respiratory tract involvement of RP.
复发性多软骨炎(RP)是一种罕见的影响软骨结构的免疫介导性疾病。呼吸道表现很常见,是发病和死亡的主要原因。本综述旨在评估肿瘤坏死因子α(TNF-α)抑制剂在RP呼吸道受累中的疗效。对2000年1月至2016年12月的MEDLINE文献进行检索,以确定所有关于RP抗TNF-α治疗的研究和病例报告。发表于英文或法文且涉及呼吸道受累患者的文章符合要求。两位作者(JB、FL)独立审查并提取了每位患者的数据,并补充了2例个人病例。根据全身和/或呼吸道标准评估治疗效果。最终分析共纳入28例患者(平均年龄:41.6岁;女性16例/男性12例)。抗TNF-α治疗分别使67.8%和60.1%的患者健康状况和呼吸道症状得到改善。这些结果表明,TNF-α抑制剂可考虑用于治疗RP的呼吸道受累。